Fueling the Next Great Wave of Data-Driven Innovation in the Life Sciences
We are on the cusp of a revolution in the biological and medical sciences. A whole human genome can now be sequenced in a matter of hours and for as little as USD 1,000, and we are moving quickly toward the USD 100 genome. Meanwhile, technologies such as Cryo-Electron Microscopy (Cryo-EM) and Molecular Dynamics are helping researchers visualize and understand cellular processes at the molecular level.
These and other technologies are opening a window into the most fundamental processes of life. Biological pathways can be illuminated, disease mechanisms can be identified, and drug discovery can be transformed from a multiyear, multi-billion dollar, trial and-error process to an efficient, data-driven workflow. Perhaps most importantly, precision medicine, with molecular level profiles and personalized treatments, will ultimately transform the way we diagnose and treat injury and disease.
Professor Knut Reinert, PhD, and his team at the Free University of Berlin are collaborating with Intel to accelerate genome analysis by optimizing critical algorithms so they run efficiently on multicore and many-core Intel® processors.
Download complete Solution Brief (PDF).
Intel's compilers may or may not optimize to the same degree for non-Intel microprocessors for optimizations that are not unique to Intel microprocessors. These optimizations include SSE2, SSE3, and SSSE3 instruction sets and other optimizations. Intel does not guarantee the availability, functionality, or effectiveness of any optimization on microprocessors not manufactured by Intel. Microprocessor-dependent optimizations in this product are intended for use with Intel microprocessors. Certain optimizations not specific to Intel microarchitecture are reserved for Intel microprocessors. Please refer to the applicable product User and Reference Guides for more information regarding the specific instruction sets covered by this notice.
Notice revision #20110804